Roivant Sciences
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ROIV and other ETFs, options, and stocks.About ROIV
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses.
CEOMatthew Gline
CEOMatthew Gline
Employees750
Employees750
HeadquartersLondon, Greater London
HeadquartersLondon, Greater London
Founded2021
Founded2021
Employees750
Employees750
ROIV Key Statistics
Market cap15.08B
Market cap15.08B
Price-Earnings ratio-39.27
Price-Earnings ratio-39.27
Dividend yield—
Dividend yield—
Average volume8.30M
Average volume8.30M
High today$21.74
High today$21.74
Low today$21.50
Low today$21.50
Open price$21.63
Open price$21.63
Volume5.53M
Volume5.53M
52 Week high$23.47
52 Week high$23.47
52 Week low$8.73
52 Week low$8.73
Stock Snapshot
As of today, Roivant Sciences(ROIV) shares are valued at $21.70. The company's market cap stands at 15.08B, with a P/E ratio of -39.27.
As of 2026-01-01, Roivant Sciences(ROIV) stock has fluctuated between $21.50 and $21.74. The current price stands at $21.70, placing the stock +0.9% above today's low and -0.2% off the high.
The Roivant Sciences(ROIV)'s current trading volume is 5.53M, compared to an average daily volume of 8.3M.
In the last year, Roivant Sciences(ROIV) shares hit a 52-week high of $23.47 and a 52-week low of $8.73.
In the last year, Roivant Sciences(ROIV) shares hit a 52-week high of $23.47 and a 52-week low of $8.73.
Analyst ratings
82%
of 11 ratingsBuy
81.8%
Hold
18.2%
Sell
0%
People also own
Based on the portfolios of people who own ROIV. This list is generated using Robinhood data, and it’s not a recommendation.